StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Friday. The firm set a “sell” rating on the stock.

InspireMD Price Performance

Shares of NSPR opened at $2.44 on Friday. The company has a market capitalization of $60.83 million, a price-to-earnings ratio of -3.21 and a beta of 0.96. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.85. The business’s 50-day moving average is $2.42 and its 200-day moving average is $2.50.

InspireMD (NYSE:NSPR) last issued its earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). The business had revenue of $1.51 million during the quarter, compared to analyst estimates of $1.38 million. InspireMD had a negative net margin of 350.35% and a negative return on equity of 55.12%. During the same quarter in the prior year, the company earned ($0.53) EPS. Equities research analysts expect that InspireMD will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. McKinley Carter Wealth Services Inc. acquired a new position in InspireMD, Inc. (NYSE:NSPR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $28,000. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.